High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets | Zendy

Amelia Ruffatti | Zendy; Marta Tonello | Zendy; Antonia Calligaro | Zendy; Teresa Del Ross | Zendy; Maria Favarò | Zendy; Margherita Zen | Zendy; Antonio Carletto | Zendy; Virginia Lotti | Zendy; Eugenia Bertoldo | Zendy; Francesco Saverio Tedesco | Zendy; Ariela Hoxha | Zendy; Domenico Biasi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets

Author(s) -

Amelia Ruffatti,

Marta Tonello,

Antonia Calligaro,

Teresa Del Ross,

Maria Favarò,

Margherita Zen,

Antonio Carletto,

Virginia Lotti,

Eugenia Bertoldo,

Francesco Saverio Tedesco,

Ariela Hoxha,

Domenico Biasi

Publication year - 2021

Publication title -

clinical and experimental rheumatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.184

H-Index - 95

eISSN - 1593-098X

pISSN - 0392-856X

DOI - 10.55563/clinexprheumatol/7cinzu

Subject(s) - medicine , antiphospholipid syndrome , thrombosis , catastrophic antiphospholipid syndrome , gastroenterology , complement system , antibody , refractory (planetary science) , immunology , physics , astrobiology

High plasma C5a and C5b-9 levels are considered a clear sign of complement activation. We aimed to evaluate the clinical significance of these two complement activation products during quiescent phases of thrombotic antiphospholipid syndrome (APS) by comparing their plasma levels in the different clinical subsets and relating them to the clinical characteristics and antiphospholipid antibody profile of the patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research